Table Of Contents
1. Market Context & Strategic Relevance
1.1 Opening Context (Why the market matters)
1.1.1 Why This Market Is Gaining Strategic Attention
1.1.2 Business Decisions This Report Supports
1.2 Scope
1.3 Research & Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035
2.3 Market Size & Forecast, By Segmentation, 2022–2035
2.3.1 Market Size By Product
2.3.2 Market Size By Application
2.3.3 Market Size By Route of Administration
2.3.4 Market Size By Distribution Channel
2.4 Market Share & Bps Analysis By Region, 2025
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1. Active Pharmaceutical Ingredient (API) & Raw Material Suppliers
3.4.2. Pharmaceutical Manufacturers & Formulators
3.4.3. Distributors, Wholesalers & Pharmacy Chains
3.4.4. Hospitals, Prescribers & Patient End Users
3.5 Industry Life Cycle Assessment
4. Statistical Insights & Trends Reporting (2025)
4.1 Prescription & Patient Volume Metrics
4.1.1 U.S. GLP-1 Receptor Agonist Prescription Volumes
4.1.2 Number of Active Patients on GLP-1 Therapy
4.1.3 New Patient Starts vs. Continuing Prescription Metrics
4.1.4 Prescription Refill & Adherence Rates
4.2 Product Adoption & Utilization Statistics
4.2.1 Brand-Wise Prescription Share & Adoption Metrics
4.2.2 Off-Label vs. Approved Indication Usage Statistics
4.2.3 Dose Titration & Treatment Continuation Rates
4.2.4 Switching & Discontinuation Metrics Across GLP-1 Products
4.3 Clinical Outcome & Efficacy Benchmarks
4.3.1 Average HbA1c Reduction & Glycemic Control Metrics
4.3.2 Average Weight Loss & BMI Reduction Benchmarks
4.3.3 Cardiovascular & Metabolic Outcome Statistics
4.3.4 Adverse Event & Tolerability Rates
4.4 Route of Administration & Delivery Metrics
4.4.1 Parenteral vs. Oral GLP-1 Utilization Statistics
4.4.2 Injection Pen & Device Usage Metrics
4.4.3 Dosing Frequency & Administration Compliance Rates
4.4.4 Patient Preference & Delivery Format Adoption
4.5 Operating Economics & Cost Metrics
4.5.1 Average Monthly & Annual Cost per GLP-1 Therapy
4.5.2 Insurance Coverage & Reimbursement Statistics
4.5.3 Out-of-Pocket & Cash-Pay Prescription Metrics
4.5.4 Prescription Channel Cost Distribution
5. U.S. GLP-1 Receptor Agonist Market Segmental Analysis & Forecast, By Product, 2022–2035, Value (USD Billion)
5.1 Introduction
5.2 Ozempic
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2022 – 2035
5.3 Trulicity
5.4 Mounjaro
5.5 Wegovy
5.6 Rybelsus
5.7 Saxenda
5.8 Victoza
5.9 Zepbound
5.10 Other Products
6. U.S. GLP-1 Receptor Agonist Market Segmental Analysis & Forecast, By Application, 2022–2035, Value (USD Billion)
6.1 Introduction
6.2 Type 2 Diabetes Mellitus
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2022–2035
6.3 Obesity
6.4 Others
7. U.S. GLP-1 Receptor Agonist Market Segmental Analysis & Forecast, By Route of Administration, 2022–2035, Value (USD Billion)
7.1 Introduction
7.2 Parenteral
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2022–2035
7.3 Oral
8. U.S. GLP-1 Receptor Agonist Market Segmental Analysis & Forecast, By Distribution Channel, 2022–2035, Value (USD Billion)
8.1 Introduction
8.2 Hospital Pharmacies
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2022–2035
8.3 Retail Pharmacies
8.4 Online Pharmacies
8.5 Others
9. U.S. GLP-1 Receptor Agonist Market Segmental Analysis & Forecast By Region, 2022–2035, Value (USD Billion)
9.1 Introduction
9.2 Northeast
9.2.1 Key Trends
9.2.2 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Product, 2022–2035
9.2.3 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Application, 2022–2035
9.2.4 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Route of Administration, 2022–2035
9.2.5 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Distribution Channel, 2022–2035
9.3 Midwest
9.3.1 Key Trends
9.3.2 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Product, 2022–2035
9.3.3 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Application, 2022–2035
9.3.4 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Route of Administration, 2022–2035
9.3.5 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Distribution Channel, 2022–2035
9.4 South
9.4.1 Key Trends
9.4.2 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Product, 2022–2035
9.4.3 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Application, 2022–2035
9.4.4 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Route of Administration, 2022–2035
9.4.5 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Distribution Channel, 2022–2035
9.5 West
9.5.1 Key Trends
9.5.2 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Product, 2022–2035
9.5.3 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Application, 2022–2035
9.5.4 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Route of Administration, 2022–2035
9.5.5 U.S. GLP-1 Receptor Agonist Market Size & Forecast, By Distribution Channel, 2022–2035
10. Competitive Landscape
10.1 Key Players' Positioning
10.2 Competitive Developments
10.2.1 Year-Wise Strategies & Development, 2022–2026
10.3 Market Share Analysis, 2025
10.4 Product/Service & Application Benchmarking
10.4.1 Product/Service Specifications & Features By Key Players
10.4.2 Product/Service Heatmap By Key Players
10.4.3 Application Heatmap By Key Players
10.5 Industry Start-Up & Innovation Landscape
10.6 Key Company Profiles
10.6.1 Novo Nordisk A/S
10.6.1.1 Company Overview & Snapshot
10.6.1.2 Product/Service Portfolio
10.6.1.3 Key Company Financials
10.6.1.4 Geographical Presence
10.6.1.5 SWOT Analysis
10.6.2 Eli Lilly and Company
10.6.3 Pfizer Inc.
10.6.4 Amgen Inc.
10.6.5 AstraZeneca plc
10.6.6 Merck & Co., Inc.
10.6.7 Boehringer Ingelheim International GmbH
10.6.8 Teva Pharmaceutical Industries Ltd.
10.6.9 Viking Therapeutics, Inc.
10.6.10 Structure Therapeutics Inc.
10.6.11 Altimmune, Inc.
10.6.12 CVS Health Corporation
10.6.13 UnitedHealth Group Incorporated
10.6.14 Walgreens Boots Alliance, Inc.
10.6.15 Hims & Hers Health, Inc.
10.6.16 McKesson Corporation
10.6.17 Cencora, Inc.
10.6.18 Cardinal Health, Inc.
10.6.19 Roche Holding AG
10.6.20 Zealand Pharma A/S
11. Analyst Recommendations
11.1 SNS Insider Opportunity Map
11.2 Industry Low-Hanging Fruit Assessment
11.3 Market Entry & Growth Strategy
11.4 Analyst Viewpoint & Suggestions On Market Growth
12. Assumptions
13. Disclaimer
14. Appendix
14.1 List Of Tables
14.2 List Of Figures
Frequently Asked Questions
Key players in the U.S. GLP-1 Receptor Agonist Market include Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Amgen Inc., AstraZeneca plc, and Merck & Co., Inc., among others.
Key opportunities include oral formulation launches, cardiometabolic label expansions, and continued domestic capacity investment easing supply constraints.
The market is driven by rising obesity and diabetes prevalence, expanding employer and commercial payer coverage, and growing telehealth prescribing access.
The Ozempic segment dominated the U.S. GLP-1 Receptor Agonist Market, accounting for approximately 33.70% share in 2025.
The South dominated the U.S. GLP-1 Receptor Agonist Market in 2025 with a 32.00% share, driven by higher regional prevalence and a large population base.
